Azelastine hydrochloride on behavioral and psychological symptoms and activities of daily living in dementia patients

Geriatrics and Gerontology International

Volumn 8, Issue 1, 2008, Pages 59-61

  Hatakeyama, Aiko ^a   Fujii, Masahiko ^b   Hatakeyama, Reiko ^a   Fukuoka, Yumiko ^a   Satoh Nakagawa, Takuma ^b   Sasaki, Hidetada ^a  

^a Akita University of Nursing and Welfare   (Japan)

^b Sendai Tomizawa Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PHTHALAZINE DERIVATIVE;

AGED; BEHAVIOR; CAREGIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; FEMALE; HOSPITALIZATION; HUMAN; JAPAN; LETTER; MALE; NURSING; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; BEHAVIORAL SYMPTOMS; CAREGIVERS; DEMENTIA; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; JAPAN; MALE; PHTHALAZINES; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 55249093001     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2008.00438.x     Document Type: Letter

References (15)

1. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-1051.
2. Norton LE, Malloy PF, Salloway S. The impact of behavioral symptoms on activities of daily living in patients with dementia. Am J Geriatr Psychiatry 2001; 9: 41-48.
3. Stolze H, Klebe S, Zechlin C, Baecker C, Friege L, Deuschi G. Falls in frequent neurological diseases: Prevalence, risk factors and aetiology. J Neurol 2004; 251: 79-84.
4. Wada H, Nakajoh K, Satoh-Nakagawa T et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001; 47: 271-276.
5. Iwasaki K, Satoh Nakagawa T, Maruyama M et al. A randomized controlled trail of a traditional Chinese medicine, Yi-Gan San, on behavioral and psychological symptoms and activities of daily living in dementia patient's. J Clin Psychiatry 2005; 66: 248-252.
6. Spector SL, Perhach JL, Rohr AS, Racheletsky GS, Katz RM, Siegal SC. Pharmacodynamic evaluation of azelastine in subjects with asthma. J Allergy Clin Immunol 1987; 80: 75-80.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association, 1994.
8. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
9. Mahoney FI, Barthel DW. Functinal evaluation: The Barthel Index. Md State Med J 1965; 14: 61-65.
10. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
11. Wallis RA, Panizzon KL. Protection from hypoxic and N-menthy-D-aspartate injury with azelastine, a leukotriene inhibitor. Eur J Pharmacol 1993; 238: 165-171.
12. Peter G. Tolerability and pharmacokinetics of single and multiple doses of azelastine hydrochloride in elderly volunteers. Arzneimittelforschung 1995; 45: 575-581.
13. Tatsumi K, Ou T, Yamada H, Yoshimura H. Studies on metabolic fate of a new antiallergic agent, azelastine (4-cp-chlorobenzyl)-2-[N- methylperhydroazepinyl-4(4)]-1-(2H)-phthalazinone hydrochloride) Jpn J Pharmacol 1980; 30: 37-48.
14. Okamura N, Yanai K, Higuchi M, et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000; 129: 115-123.
15. Oken RJ. Antihistamines, a possible risk factor for Alzheimer's disease. Med Hypotheses 1995; 44: 47-48.